MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Bladder and Urothelial Cancer Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,070 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,070 works in the cohort · of 4,299,418page 45 of 62

Labels cover 8 of 3,070 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,070 of 3,070 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affvenueno abstractunlabeled
Bladder cancer: Validating what we've got
Alexandre R. Zlotta
2013· article· en· Canadian Urological Association Journal· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y
Terence W. Friedlander, Peter H. O’Donnell, M. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig +14 more
2025· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
venueno affunlabeled
A Second-Look at the Repeat Resections of Bladder Tumors
Madison Lyon, Sharon White, Taylor Goodstein, Madeline Koerner, Alexandra Colvin, Colin O’Donnell +2 more
2018· article· en· World Journal of Nephrology and Urology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Editorial Comment
J. Curtis Nickel
2013· editorial· es· Urology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
The Initial Report of RTOG 0524: Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer
Huong Pham, Chen Hu, M. Dror Michaelson, Douglas M. Dahl, Chin‐Lee Wu, Richard M. Whittington +8 more
2014· article· en· International Journal of Radiation Oncology*Biology*Physics· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
venueno affunlabeled
Bladder Melanosis
Donnacha Hogan, Nick Mayer, Derek Hennessey
2022· article· en· Journal of Endoluminal Endourology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About